Alnylam Pharmaceuticalsvs.Regeneron
ALNY vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 1.7× larger than Alnylam Pharmaceuticals by market cap; Regeneron trades at the lower P/E (15.7 vs 69.1); year to date, Regeneron leads (−13.9% vs −24.9%).
Side by side
| ALNY | REGN | |
|---|---|---|
| Market cap | $39.9B | $69.7B |
| Price | $298.76 | $664.52 |
| Today | −4.5% | −0.5% |
| Return YTD | −24.9% | −13.9% |
| Return 1Y | −7.4% | +18.7% |
| P/E | 69.1 | 15.7 |
| P/S | 9.3 | 4.7 |
| P/B | 37.1 | 2.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Full ALNY profile →RegeneronREGN
American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.
Full REGN profile →More comparisons in Biotech & innovation
See where ALNY and REGN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →